Literature DB >> 32333618

HIF1α-dependent metabolic reprogramming governs mesenchymal stem/stromal cell immunoregulatory functions.

Rafael Contreras-Lopez1, Roberto Elizondo-Vega1,2, Maria Jose Paredes1, Noymar Luque-Campos1, Maria Jose Torres3, Gautier Tejedor4, Ana Maria Vega-Letter5,6, Aliosha Figueroa-Valdés5,6, Carolina Pradenas1, Karina Oyarce7, Christian Jorgensen4, Maroun Khoury5,6, Maria de Los Angeles Garcia-Robles2, Claudia Altamirano3, Farida Djouad4, Patricia Luz-Crawford1.   

Abstract

Hypoxia-inducible factor 1 α (HIF1α), a regulator of metabolic change, is required for the survival and differentiation potential of mesenchymal stem/stromal cells (MSC). Its role in MSC immunoregulatory activity, however, has not been completely elucidated. In the present study, we evaluate the role of HIF1α on MSC immunosuppressive potential. We show that HIF1α silencing in MSC decreases their inhibitory potential on Th1 and Th17 cell generation and limits their capacity to generate regulatory T cells. This reduced immunosuppressive potential of MSC is associated with a metabolic switch from glycolysis to OXPHOS and a reduced capacity to express or produce some immunosuppressive mediators including Intercellular Adhesion Molecule (ICAM), IL-6, and nitric oxide (NO). Moreover, using the Delayed-Type Hypersensitivity murine model (DTH), we confirm, in vivo, the critical role of HIF1α on MSC immunosuppressive effect. Indeed, we show that HIF1α silencing impairs MSC capacity to reduce inflammation and inhibit the generation of pro-inflammatory T cells. This study reveals the pivotal role of HIF1α on MSC immunosuppressive activity through the regulation of their metabolic status and identifies HIF1α as a novel mediator of MSC immunotherapeutic potential.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  HIF1α; MSCs; glycolytic; immunomodulation; immunosuppression; metabolic reprogramming; metabolism

Year:  2020        PMID: 32333618     DOI: 10.1096/fj.201902232R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

Review 1.  Translating MSC Therapy in the Age of Obesity.

Authors:  Lauren Boland; Laura Melanie Bitterlich; Andrew E Hogan; James A Ankrum; Karen English
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

2.  The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential.

Authors:  Rafael Contreras-Lopez; Roberto Elizondo-Vega; Noymar Luque-Campos; María José Torres; Carolina Pradenas; Gautier Tejedor; María José Paredes-Martínez; Ana María Vega-Letter; Mauricio Campos-Mora; Yandi Rigual-Gonzalez; Karina Oyarce; Magdiel Salgado; Christian Jorgensen; Maroun Khoury; María de Los Ángeles Garcia-Robles; Claudia Altamirano; Farida Djouad; Patricia Luz-Crawford
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

3.  Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells.

Authors:  Katarzyna Zielniok; Anna Burdzinska; Beata Kaleta; Radoslaw Zagozdzon; Leszek Paczek
Journal:  Cells       Date:  2020-11-01       Impact factor: 6.600

Review 4.  Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells.

Authors:  Claudia Terraza-Aguirre; Mauricio Campos-Mora; Roberto Elizondo-Vega; Rafael A Contreras-López; Patricia Luz-Crawford; Christian Jorgensen; Farida Djouad
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

Review 5.  The role and mechanism of mitochondrial functions and energy metabolism in the function regulation of the mesenchymal stem cells.

Authors:  Wanhao Yan; Shu Diao; Zhipeng Fan
Journal:  Stem Cell Res Ther       Date:  2021-02-17       Impact factor: 6.832

Review 6.  Musculoskeletal Progenitor/Stromal Cell-Derived Mitochondria Modulate Cell Differentiation and Therapeutical Function.

Authors:  Christian Jorgensen; Maroun Khoury
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

Review 7.  Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases.

Authors:  Sara Rolandsson Enes; Anna D Krasnodembskaya; Karen English; Claudia C Dos Santos; Daniel J Weiss
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

8.  HIF-Overexpression and Pro-Inflammatory Priming in Human Mesenchymal Stromal Cells Improves the Healing Properties of Extracellular Vesicles in Experimental Crohn's Disease.

Authors:  Marta Gómez-Ferrer; Elena Amaro-Prellezo; Akaitz Dorronsoro; Rafael Sánchez-Sánchez; Ángeles Vicente; Jesús Cosín-Roger; María Dolores Barrachina; María Carmen Baquero; Jaris Valencia; Pilar Sepúlveda
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

9.  microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.

Authors:  Dong Yang; Tianyang Xu; Lin Fan; Kaiyuan Liu; Guodong Li
Journal:  J Exp Clin Cancer Res       Date:  2020-09-24

Review 10.  Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis.

Authors:  Elena Bargagli; Rosa Metella Refini; Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Lorenza Vantaggiato; Luca Bini; Claudia Landi
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.